Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Ampio Pharmaceuticals, Inc. (AMPE) Investors of Class Action and to Actively Participate

AMPE

NEW YORK, Aug. 19, 2022 /PRNewswire/ -- Attorney Advertising --Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ampio Pharmaceuticals, Inc. ("Ampio" or "the Company") (NYSE: AMPE) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Ampio securities between December 29, 2020 and August 3, 2022, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ampe.

Bronstein, Gewirtz & Grossman, LLC

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The Complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business operations and prospects. Specifically, defendants: (1) inflated the Company's true ability to successfully file a Biologics License Application (BLA) for Ampio; (2) inflated the results of the AP-013 study of Ampion (the Company's lead product with "unique immunomodulatory action and anti-inflammatory effects" used to treat individuals with inflammatory conditions including, but not limited to, severe osteoarthritis of the knee (OAK)) and the timing of unblinding the data from the AP-013 study; and (3) that, as a result, of the foregoing, defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/ampe or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Ampio you have until October 17, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-bronstein-gewirtz--grossman-llc-notifies-ampio-pharmaceuticals-inc-ampe-investors-of-class-action-and-to-actively-participate-301608819.html

SOURCE Bronstein, Gewirtz & Grossman, LLC